Emory University Hospital - Midtown

A part of Emory Healthcare, the Emory University Hospital Midtown offers a full range of services in midtown Atlanta. The hospital is accredited by the American College of Surgeons Commission on Cancer as a Teaching Hospital Cancer Program. The hospital is also accredited by the American College of Radiology (ACR). The hospital’s mission is to care for patients and their families with concern not only for their illnesses, but also for their mental, emotional and spiritual well-being.

Treatment Sites in Georgia

Primary Location

550 Peachtree Street NE
Atlanta, GA 30308
404-686-4411 (p)
www.emoryhealthcare.org

driving directions

Doctors:

Ana Antun MD

James K. Bennett

Leon Bernal MD

Kenneth Cardona MD

Grant W. Carlson MD

Daniel J. Carr MD

Bradley C. Carthon, MD, PhD

Amy Y. Chen MD

Suephy C. Chen MD, MS

Douglas C. Collins MD

Ian R. Crocker MD, FACR

Keith A. Delman MD, FACS

Roberto R. Diaz MD

Scott H. Edelman MD

Natia Esiashvili MD

Lisa Flowers MD

Seth D. Force MD

Karen D. Godette MD

Alan N. Gordon MD

Wayne B. Harris MD

Natalyn N. Hawk MD

Bruce W. Hershatter MD

Kristin Higgins MD

Christopher Ho MD

Ira R. Horowitz MD, SM, FACOG, FACS

Ashesh B. Jani MD

Cassandra Josephson MD

Azeem S Kaka MD

Mohammad K Khan MD, PhD

Namita Khanna MD

Omer Kucuk MD

Jerome C. Landry MD

David H. Lawson MD

Mary Jo Lechowicz MD

Albert Losken MD

Shishir K. Maithel MD

Peter T. Nieh MD

Ajay K. Nooka MD, MPH

Jeffrey J. Olson MD

Thomas A. Olson MD

Taofeek K. Owonikoko MD

Suchita Pakkala MD

John G. Pattaras MD

Rogsbert F Phillips MD, FACS

Suresh S. Ramalingam MD

William Read , MD

Satyanarayan K. Reddy MD

Maria J. Ribeiro MD

Monica Rizzo MD

Seth A Rosen MD

Peter J. Rossi MD

Maria Russell MD

Nabil F. Saba MD, FACP

Joseph Shelton MD

Dong Moon Shin MD

Charles A. Staley MD

Liza J. Stapleford MD

Edmund K. Waller MD, PhD, FACP

Clinical Trials in Georgia

6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type: Unknown Primary

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type: Leukemia, Lymphoma

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which has Spread to the Lymph Nodes (The INSPIRE Study)
Cancer Type: Bladder Cancer

Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients with Stage II-III Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Cancer Type: Pancreatic Cancer

Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer
Cancer Type: Lung Cancer, Unknown Primary

Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Cancer Type: Lung Cancer

De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Eflornithine and/or Sulindac in Preventing Recurrence of High-Risk Adenomas and Second Primary Disease in Patients with Stage 0-III Colon or Rectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type: Lung Cancer

Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Cancer Type: Head and Neck Cancer, Unknown Primary

Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer
Cancer Type: Lung Cancer

KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type: Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary

Low Dose Y90 Microspheres for the Planning of Radioembolization Therapy in Patients with Stage A-C Liver Cancer
Cancer Type: Liver Cancer / Hepatoblastoma, Unknown Primary

Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type: Colon/Rectal Cancer, Unknown Primary

Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
Cancer Type: Esophogeal Cancer

Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type: Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations
Cancer Type: Bile Duct Cancer, Brain & Spinal Cord Tumor

Osimertinib in Treating Patients with Stage IIIB-IV or Recurrent Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Cancer Type: Lung Cancer

Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type: Pancreatic Cancer, Unknown Primary

Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Cancer Type: Head and Neck Cancer

Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors
Cancer Type: Solid Tumor, Unknown Primary

Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type: Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary

Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients with IDH Mutant Grade II or III Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Cancer Type: Brain & Spinal Cord Tumor, Brain Tumor

Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Cancer Type: Head and Neck Cancer

TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
Cancer Type: Bile Duct Cancer

Telotristat Ethyl in Promoting Weight Stability in Patients with Recurrent Advanced Pancreatic Adenocarcinoma
Cancer Type: Pancreatic Cancer, Unknown Primary

Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma
Cancer Type: Sarcoma, Unknown Primary

Testing Cabozantinib in Patients with Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Cancer Type: Neuroendocrine Tumor

Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type: Head and Neck Cancer, Unknown Primary

Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity
Cancer Type: Breast Cancer

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
Cancer Type: Lung Cancer

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Cancer Type: Unknown Primary

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
Cancer Type: Lung Cancer

Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
Cancer Type: Uterine Cancer

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Cancer Type: Bladder Cancer, Kidney Cancer, Penile Cancer, Urethral Cancer

Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type: Neuroendocrine Tumor, Unknown Primary

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab with or without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers
Cancer Type: Head and Neck Cancer

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
Cancer Type: Breast Cancer

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas
Cancer Type: Brain & Spinal Cord Tumor

**GeorgiaCancerInfo is not a medical practice. This is an informational web site provided by Georgia CORE, a nonprofit striving to provide current and comprehensive information on cancer care in Georgia through this website. If you find erroneous or missing information, please contact us.